BioCardia, Inc. (BCDA): Depreciation & Amortization
$24.0K
Year ended 2025-12-31
$13.0K
Trailing 12 months to 2026-06-30
-33.6%
3-year compound annual growth
-18.8%
5-year compound annual growth
-6.5%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.0K | -64.2% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $67.0K | -20.2% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $84.0K | +2.4% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $82.0K | +36.7% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $60.0K | -11.8% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $68.0K | -38.7% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $111.0K | +26.1% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $88.0K | +12.8% | 2020-04-09, From 2018-01-01 |
| 2017-12-31 | $78.0K | +100.0% | 2020-04-09, From 2017-01-01 |
| 2016-12-31 | $39.0K | -17.0% | 2019-04-02, From 2016-01-01 |
| 2015-12-31 | $47.0K | n/a | 2018-03-16, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | 2025-12-31 | $24.0K | -64.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $8.58M | -3.1% |
| Amgen Inc (AMGN) | 2025-12-31 | $5.17B | -7.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $78.75M | +13.0% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $1.38M | -16.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $97.36M | -11.4% |
| Biogen Inc. (BIIB) | 2025-12-31 | $779.90M | +15.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $699.0K | +19.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.39M | +11.5% |
Compare BCDA, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗